Integra LifeSciences Holdings Corporation (IART)

Market Cap	1.45B +45.5%
Revenue (ttm)	1.65B +1.6%
Net Income	-7.24M
EPS	-0.10
Shares Out	77.77M
PE Ratio	n/a
Forward PE	7.27
Dividend	n/a
Ex-Dividend Date	n/a

Volume	283,092
Open	17.95
Previous Close	17.38
Day's Range	17.94 - 18.65
52-Week Range	8.70 - 20.49
Beta	1.21
Analysts	Hold
Price Target	19.56 (+5.27%)
Earnings Date	Jul 29, 2026

About IART

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical, ear, nose, throat, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates through Codman Specialty Surgical and Tissue Technologies segments. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment. It also offers after...

• Industry: Medical Devices
• Sector: Healthcare
• IPO Date: Aug 16, 1995
• Employees: 4,427
• Stock Exchange: NASDAQ
• Ticker Symbol: IART
• Website: https://www.integralife.com

Financial Performance

In 2025, IART's revenue was $1.64 billion, an increase of 1.53% compared to the previous year's $1.61 billion. Losses were -$516.47 million, 7337.7% more than in 2024.

Analyst Summary

According to 12 analysts, the average rating for IART stock is "Hold." The 12-month stock price target is $19.56, which is an increase of 5.27% from the latest price.

Price Target

$19.56

(5.27% upside)

Analyst Consensus: Hold

Data Sources: S&P Global Market Intelligence, CBOE, and more

Fundamental and historical data is provided by S&P Global Market Intelligence. Real-time stock price data is provided by CBOE and 15-minute delayed consolidated tape pricing data is provided by Nasdaq UTP.

Last checked:

Aug 13, 2026

Data Sources Report a data error